You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

TENAPANOR HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for tenapanor hydrochloride and what is the scope of freedom to operate?

Tenapanor hydrochloride is the generic ingredient in two branded drugs marketed by Ardelyx Inc and is included in two NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tenapanor hydrochloride has eighty-five patent family members in twenty-eight countries.

One supplier is listed for this compound.

Summary for TENAPANOR HYDROCHLORIDE

International Patents:	85
US Patents:	6
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	17
What excipients (inactive ingredients) are in TENAPANOR HYDROCHLORIDE?	TENAPANOR HYDROCHLORIDE excipients list
DailyMed Link:	TENAPANOR HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TENAPANOR HYDROCHLORIDE

Generic Entry Dates for TENAPANOR HYDROCHLORIDE^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial Dosage: TABLET;ORAL
Generic Entry Dates for TENAPANOR HYDROCHLORIDE^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TENAPANOR HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ardelyx	Phase 4
Ardelyx	Phase 2/Phase 3
Kyowa Hakko Kirin Co., Ltd	Phase 2

See all TENAPANOR HYDROCHLORIDE clinical trials

Pharmacology for TENAPANOR HYDROCHLORIDE

Drug Class	Sodium-Hydrogen Exchanger 3 Inhibitor
Mechanism of Action	Organic Anion Transporting Polypeptide 2B1 Inhibitors Sodium-Hydrogen Exchanger 3 Inhibitors

US Patents and Regulatory Information for TENAPANOR HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-003	Oct 17, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TENAPANOR HYDROCHLORIDE

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Russian Federation	2018143592	NHE3-СВЯЗЫВАЮЩИЕ СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ТРАНСПОРТА ФОСФАТОВ	⤷ Try a Trial
Israel	284624	תרכובות קושרות- nhe3 ושיטות לעיכוב הובלת פוספאט (Nhe3-binding compounds and methods for inhibiting phosphate transport)	⤷ Try a Trial
Hong Kong	1221400	用於抑制磷酸鹽轉運的結合化合物和方法 (NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT NHE3)	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2014169094		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for TENAPANOR HYDROCHLORIDE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TENAPANOR HYDROCHLORIDE

Recent Clinical Trials for TENAPANOR HYDROCHLORIDE

Pharmacology for TENAPANOR HYDROCHLORIDE

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TENAPANOR HYDROCHLORIDE